公开(公告)号：EP3911680A1

公开(公告)日：2021-11-24

申请号：EP20741290.9

申请日：2020-01-16

Applicant: University Health Network

Inventor： BROKX, Richard ,  MASON, Jacqueline M. ,  BRAY, Mark R.

IPC: C07K16/28 ,  A61K39/395 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  A61P37/06 ,  C12N15/13 ,  C12P21/08

公开(公告)号：EP4135695A1

公开(公告)日：2023-02-22

申请号：EP21788245.5

申请日：2021-04-12

Applicant: University Health Network

Inventor： BRAY, Mark R. ,  MASON, Jacqueline M. ,  WEI, Xin ,  DUNCAN, Gordon

IPC: A61K31/4436 ,  A61P37/02 ,  C07D495/04

公开(公告)号：EP3924388A1

公开(公告)日：2021-12-22

申请号：EP20756467.5

申请日：2020-02-14

Applicant: University Health Network

Inventor： BROKX, Richard ,  MASON, Jacqueline M. ,  BRAY, Mark R.

IPC: C07K16/28 ,  A61K39/395 ,  A61P31/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  C12N15/13 ,  C12N5/10 ,  C12P21/08

公开(公告)号：EP3057593A1

公开(公告)日：2016-08-24

申请号：EP14853347.4

申请日：2014-10-03

Applicant: University Health Network

Inventor： HEDLEY, David W. ,  LOHSE, Ines ,  MASON, Jacqueline M. ,  BRAY, Mark R.

IPC: A61K31/5377 ,  A61K31/416 ,  A61P35/00 ,  C07D413/14

CPC classification number: A61K31/5377 ,  A61K31/7068 ,  A61K33/24 ,  A61K45/06 ,  C07D403/08 ,  C07D413/14 ,  A61K2300/00

Abstract: The invention is related to a method of treating a subject with pancreatic cancer with administration of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof.

公开(公告)号：EP2588110A1

公开(公告)日：2013-05-08

申请号：EP11800027.2

申请日：2011-07-04

Applicant: University Health Network

Inventor： PAN, Guohua ,  MASON, Jacqueline M. ,  WEI, Xin ,  FEHER, Miklos

IPC: A61K31/496 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4439 ,  A61P35/00

CPC classification number: A61K31/416 ,  A61K31/4439 ,  A61K31/495 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5377

Abstract: Provided herein are methods, uses and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation, hi particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist, and identifying a patient that is likely to be responsive to PLK4 antagonist therapy, if PTEN gene mutation is present.